PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DB25FUQMS4569510083!ocrevus 300 MG 10 ML VIAL 10ml — Amerisourcebergen Drug Corp

Amerisourcebergen Drug Corp holds $19.3B across 1,357,999 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DB25D3404. PoP ended Oct 9, 2025 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support

Awarding office

Amerisourcebergen Drug Corp

Recipient

Oct 9, 2025

PoP end

$120K

Obligated

$120K

Potential

424210

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Amerisourcebergen Drug Corp — $90

Contract facts

Federal

Contract numberSPE2DB25FUQMS

Also listed asSPE2DB25D3404-SPE2DB25FUQMS

AgencyDla Troop Support

Awarding officeDla Troop Support

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentAmerisourcebergen Drug Corp

CAGE1XUY5

UEIKABZK8W6PQT3

NAICS424210

No full NAICS 424210 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVSPE2DB25D3404

Place of performanceCONSHOHOCKEN PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startSep 18, 2025

PoP end (current)Oct 9, 2025

Obligated$120K

Current value$120K

Potential value$120K

4569510083!OCREVUS 300 MG/10 ML VIAL 10ML is a federal award for Dla Troop Support held by Amerisourcebergen Drug Corp. Estimated value $120K ($120K obligated). Current period of performance ends Oct 9, 2025. Place of performance: CONSHOHOCKEN PA.

4569510083!OCREVUS 300 MG/10 ML VIAL 10ML

Recompete timing

Public

● Past PoP end (316 days ago)

Current PoP ended Oct 9, 2025 (316 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Amerisourcebergen Drug Corp — $19.3B obligated across 1,357,999 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($19.3B) · all agencies

Department of Defense (DOD)$19.3B · 100%Department of Health and Human Services (HHS)$7.6M · 0%Department of Veterans Affairs (VA)$5.9M · 0%Department of Justice (DOJ)$68K · 0%

Open full company profile →

Related awards

Same parent · incumbent

36C77026P0121

DROSPIRENONE

$321K

Sep 27, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract SPE2DB25FUQMS?

SPE2DB25FUQMS (4569510083!ocrevus 300 MG 10 ML VIAL 10ml) is a Dla Troop Support award with a potential value of $120K, currently held by Amerisourcebergen Drug Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DB25FUQMS?

Dla Troop Support awarded SPE2DB25FUQMS to Amerisourcebergen Drug Corp (potential $120K).

Who is the incumbent on SPE2DB25FUQMS?

Amerisourcebergen Drug Corp is the incumbent with $19.3B across 1357999 related awards in SCOUT’s public footprint. The current period of performance ends Oct 9, 2025.

When does Amerisourcebergen Drug Corp’s SPE2DB25FUQMS come up for recompete?

SCOUT tracks a period-of-performance end of Oct 9, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 11, 2026 · refreshed monthlyLatest procurement action Sep 18, 2025